3 Dividend Stocks to Hold for the Long Haul

The article is broadly constructive on Bristol Myers Squibb, Merck, and Medtronic, highlighting dividend yields of 4.4%, 3.0%, and 3.6%, respectively, alongside continued payout growth and improving business fundamentals. Bristol Myers reported Q1 revenue of $11.5B (+3% YoY), Merck posted $525M in first-quarter Winrevair sales (+88% YoY) and gained approval for Keytruda Qlex, and Medtronic is advancing growth via its PFA and Hugo robot-assisted surgery platforms. The piece is primarily an investor opinion column, so the likely market impact is limited.

Analysis

The market is still discounting these three as “slow-growth dividend names,” but the more important setup is self-help optionality. In all three cases, near-term earnings are less about organic demand inflection and more about portfolio reshaping: patent-extension maneuvers, pipeline monetization, and capital allocation discipline. That means the upside is not linear; once investors believe the current product bridge will outlast the next patent risk window, multiples can re-rate faster than the underlying revenue base.

BMY and MRK look like the cleaner duration trades because the catalyst path is measurable over the next 6-18 months. For BMY, the key second-order effect is that a successful Eliquis successor would not just preserve revenue, it would protect the dividend narrative and reduce balance-sheet skepticism tied to patent cliffs. For MRK, the subcutaneous franchise extension is strategically more important than the market is giving it credit for: it shifts the Keytruda debate from a hard patent wall to a managed transition, which should compress perceived loss-of-exclusivity risk and support a rerating in the stock before the revenue inflection actually shows up.

MDT is a slower-burning operational turnaround, but the spinoff is the kind of move that can unlock margin visibility without requiring heroic top-line assumptions. The underappreciated angle is competitive: if the robotic surgery launch gains even modest traction, it doesn’t need to beat the category leader to matter; a low-single-digit share grab in an underpenetrated market can add enough incremental growth to change the multiple. The main risk across the group is that the market is treating these catalysts as binary and already discounted; if launch curves underwhelm for two consecutive quarters, the stocks likely revert to being viewed as yield vehicles rather than compounders.

Key Decisions for Investors

• Long MRK vs. long-duration healthcare defensives: build a 3-9 month pair where MRK outperforms lower-catalyst dividend peers if subcutaneous Keytruda adoption and diversification evidence continue; target 8-12% relative upside with ~5% downside if launch traction stalls.
• Buy BMY on weakness into the next quarter, with a 6-12 month horizon: the risk/reward improves if the market keeps pricing the next patent cliff as a clean earnings reset; upside is a rerating toward a pipeline-supported multiple, while downside is capped by the yield unless pipeline execution disappoints materially.
• Initiate a small tactical long MDT ahead of the next two earnings prints, sized as a turnaround basket position: the spinoff and product-cycle narrative can re-rate the stock over 6-18 months, but only if margin progression becomes visible; use a tight stop if guidance implies continued mix drag.
• Pair trade: long BMY / short a low-yield large-cap pharma with less near-term pipeline visibility for a 6-month trade; the thesis is that patent-risk discounting is overdone in BMY relative to self-help optionality.
• Sell downside skew rather than outright sell calls on MRK or BMY: the dividend floor and event-driven catalysts make covered-call monetization more attractive than bearish outright exposure, especially over the next 1-2 quarters.